Investigative trial in the United States to evaluate XIFAXAN® in combination therapy to potentially address the symptoms of gastrointestinal distress and pulmonary compromise associated with COVID-19 infection
Latest Information Update: 14 May 2020
At a glance
- Drugs Rifaximin (Primary)
- Indications COVID 2019 infections; Gastrointestinal disorders; Lung disorders
- Focus Therapeutic Use
- 14 May 2020 New trial record